Enterprise AI Analysis
DSSCC Net Enhanced Skin Cancer Classification Using SMOTE Tomek and Optimized Convolutional Neural Network
Skin cancer is a major global health concern where early detection is critical. Traditional diagnostic methods are prone to errors. This analysis details DSSCC-Net, a deep CNN model integrated with SMOTE-Tomek oversampling, which significantly improves classification accuracy and effectively handles class imbalance in dermoscopic datasets, demonstrating state-of-the-art performance for real-world clinical integration.
Executive Impact & Key Performance Indicators
DSSCC-Net sets a new benchmark in skin cancer classification, addressing critical challenges in data imbalance and computational efficiency, leading to significant improvements in diagnostic accuracy.
0
Average Accuracy
0
Precision
0
Recall
0
AUC Score
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Model Architecture
Performance Evaluation
Class Imbalance Handling
Deployment & Interpretability
Optimized Deep CNN Architecture
The DSSCC-Net features a novel, optimized Convolutional Neural Network (CNN) architecture designed specifically for skin lesion classification. It comprises five convolutional blocks, each followed by ReLU activation and MaxPooling layers, and integrates dropout for regularization. The final Softmax layer provides classification probabilities across seven skin cancer classes, ensuring an efficient and robust design for accurate diagnosis.
Enterprise Process Flow
Input Layer (28x28x3)
→
Conv2D_1 (32 filters)
→
MaxPooling2D_1 (2x2)
→
Conv2D_2 (64 filters)
→
MaxPooling2D_2 (2x2)
→
Conv2D_3 (128 filters)
→
MaxPooling2D_3 (2x2)
→
Flatten Layer
→
Dense_1 (128 nodes)
→
Dropout (0.5)
→
Dense_2 (7 classes / Softmax)
State-of-the-Art Performance
DSSCC-Net achieved an impressive 97.82% average accuracy, demonstrating superior performance across HAM10000, ISIC 2018, and PH2 datasets. Its balanced precision (97%), recall (97%), and a high AUC of 99.43% highlight its effectiveness in distinguishing between skin lesion classes, surpassing existing state-of-the-art models.
97.82%
Overall Classification Accuracy
| Classifier | Accuracy (%) | Precision (%) | Recall (%) | F1-Score (%) | AUC | Model Size (MB) | Inference (ms) |
|---|---|---|---|---|---|---|---|
| VGG-16 | 91.12 | 92.09 | 90.43 | 91.13 | 99.02 | 33.6 | 28.1 |
| VGG-19 | 91.68 | 92.23 | 90.57 | 91.71 | 98.14 | 39.6 | 32.7 |
| Enhanced VGG-19 | 92.51 | 92.95 | 91.40 | 92.17 | 98.75 | 43.1 | 36.2 |
| ResNet-152 | 89.32 | 90.73 | 88.21 | 89.27 | 98.74 | 230.0 | 45.5 |
| EfficientNet-B0 | 89.46 | 90.21 | 88.21 | 89.31 | 98.43 | 16.5 | 23.2 |
| Inception-V3 | 91.82 | 92.28 | 91.12 | 91.76 | 99.06 | 92.1 | 27.4 |
| MobileNetV3 | 91.97 | 92.13 | 90.51 | 91.78 | 98.95 | 3.7 | 11.3 |
| ShuffleNet | 90.43 | 90.89 | 89.76 | 90.23 | 98.41 | 2.5 | 9.7 |
| Swin Transf. | 95.33 | 95.14 | 94.62 | 94.87 | 99.11 | 89.7 | 27.2 |
| ConvNeXt | 94.56 | 94.81 | 94.09 | 94.45 | 99.05 | 87.2 | 28.4 |
| DSSCC-Net | 98.00 | 97.00 | 97.00 | 97.00 | 99.43 | 3.42 | 12.6 |
Robust Class Imbalance Handling with SMOTE-Tomek
The HAM10000 dataset, like many medical imaging datasets, suffers from severe class imbalance, where certain lesion types (e.g., melanoma) are significantly underrepresented. This imbalance can lead to biased models that favor majority classes. DSSCC-Net effectively addresses this by integrating SMOTE-Tomek, which generates synthetic samples for minority classes and removes ambiguous samples near class boundaries, ensuring balanced training and improved minority-class detection, crucial for critical diagnoses.
Clinical Impact: Minimizing False Negatives in Melanoma
Missing melanoma cases can have severe, life-threatening consequences due to delayed diagnosis. DSSCC-Net achieved a recall of 97% for melanoma, significantly reducing false negatives compared to prior models (typically <90%). This is paramount in clinical screening, where sensitivity is often more critical than overall accuracy. Our robust SMOTE-Tomek integration ensures that even rare, malignant lesions are accurately detected, providing a critical advantage in patient safety.
Deployment Readiness & Interpretability for Clinical Use
DSSCC-Net is designed for practical clinical deployment, featuring a compact model size of 3.42MB and fast inference times (12.6ms on RTX 3060, 132ms on Raspberry Pi 4). Its high interpretability, achieved through Grad-CAM visualizations, allows dermatologists to understand the specific regions of an image the model focuses on, enhancing trust and clinical validation. The average Dice coefficient (83.0%) and IoU (71.7%) further confirm its strong spatial alignment with expert annotations.
3.42MB
Compact Model Size
This efficiency and interpretability make DSSCC-Net a practical, reliable tool for early and accurate skin cancer diagnosis in diverse clinical settings, including low-resource and edge devices.
Calculate Your Potential ROI with Enterprise AI
Estimate the efficiency gains and cost savings your organization could achieve by implementing advanced AI solutions like DSSCC-Net.
ROI Estimator
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
A phased approach to integrating advanced AI, ensuring seamless transition and maximized impact for your enterprise.
Phase 01: Strategic Assessment & Data Preparation
Comprehensive analysis of existing data infrastructure, identification of key integration points for skin lesion datasets (e.g., HAM10000, ISIC 2018), and implementation of robust data preprocessing and balancing strategies like SMOTE-Tomek.
Phase 02: Model Adaptation & Training
Customization of the DSSCC-Net architecture to specific enterprise requirements, extensive training on prepared datasets, and fine-tuning to optimize performance metrics such as accuracy, precision, and recall while monitoring for overfitting.
Phase 03: Validation, Interpretability & Integration
Rigorous cross-dataset validation, in-depth interpretability analysis using techniques like Grad-CAM to ensure clinical trust, and seamless integration of the trained model into existing diagnostic workflows and IT infrastructure.
Phase 04: Deployment, Monitoring & Optimization
Deployment of the lightweight DSSCC-Net model to production environments (including edge devices), continuous monitoring of its performance, and ongoing optimization based on real-world feedback to maintain state-of-the-art diagnostic capabilities.
Ready to Transform Your Diagnostic Capabilities?
Leverage the power of DSSCC-Net to achieve unparalleled accuracy and efficiency in skin cancer detection. Book a consultation with our AI experts to design a tailored strategy for your organization.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat